Polyclonal Antibodies in Renal Transplantation-A Relook

Transplantation Proceedings

Volumn 39, Issue 3, 2007, Pages 766-772

  Sidhu, M S ^a   Nayak, K S ^a   Subhramanyam, S V ^a   Sankar, A ^a  

^a Global Hospitals   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PREDNISOLONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVASCULARIZATION; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANTIBODIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 34147095260     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.01.072     Document Type: Article

References (71)

1. Kaden J., May G., Strobelt V., et al. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 29 (1997) 344
2. Brent L. A history of transplantation immunology (1997), Academic Press, New York
3. Metchnikoff E. Étude sur la resorption des cellules. Ann Inst Pasteur 13 (1899) 737
4. Woodruff M.F.A., and Forman B. Effects of antilymphocyte serum on suspension of lymphocytes in vitro. Nature 168 (1951) 36
5. Gibson T., and Medawar P.B. The fate of skin homografts in man. J Anat 77 (1943) 299
6. Medawar P.B. The behaviour and fate of skin autografts and skin homografts in rabbits. J Anat 78 (1944) 176
7. Monaco A.P. Antiserum to lymphocytes: prolonged survival of canine renal allografts. Science 153 (1966) 1264
8. Starzl T.E., Marchioro T.L., Hutchinson D.E., et al. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 5 suppl (1967) 1100
9. Szczech L.A., Berlin J.A., Aradhye S., et al. Effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 8 (1997) 1771
10. Belitsky P., MacDonald A.S., Lawen J., et al. Use of rabbit anti-thymocyte globulin for induction immunosuppression in high-risk kidney transplant recipients. Transplant Proc 29 suppl 7 (1997) 16S
11. Haririan A., Morawski K., Sillix D.H., et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 79 (2005) 716
12. Cecka J.M., Gjertson D., and Terasaki P.I. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?. Transplant Proc 25 (1993) 548
13. Bell L., Girardin C., Sharma A., et al. Lymphocyte subsets during and after rabbit antithymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion. Transplant Proc 29 (1997) 6S
14. Cantarovich D., Giral-Classe M., Hourmant M., et al. Prevention of acute rejection with anti-thymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol Dial Transplant 15 (2000) 1673
15. Cosimi A.B. Antilymphocyte globulins and monoclonal antibodies. In: Morris P.J. (Ed). Kidney transplantation: Principle and practice (1988), Saunders, Philadelphia 343
16. Greger B., Reis H.J., Mellert J., et al. Rejection treatment by polyclonal antibodies in kidney transplantation: reliable therapy without severe side effects. Transpl Proc 20 5 Suppl 6 (1988) 9
17. Storb R., Gluckman E., Thomas E.D., et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 44 (1974) 56
18. Marsh J., Schrezenmeier H., Marin P., et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 93 (1999) 219
19. Ringden O., Remberger M., Carlens S., et al. Low incidence of acute graft-versus- host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 66 (1998) 620
20. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186
21. Starzl T.E., Marchioro T.L., Porter K.A., et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 124 (1967) 301
22. Bonnefoy-Berard N., Vincent C., and Revillard J.P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51 (1991) 669
23. Bourdage J.S., and Hamlin D.M. Comparative polyclonal antilymphocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 59 (1995) 1194
24. Bonnefoy-Berard N., and Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15 (1996) 435
25. Brennan D.C., Flavin K., Lowell J.A., et al. A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67 (1999) 1011
26. Genestier L., Fournel S., Flacher M., et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 91 (1998) 2360
27. Merion R.M., Howell T., and Bromberg J.S. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation 65 (1998) 1481
28. Kirby J.A., Lin Y., Browell D.A., et al. Renal allograft rejection: examination of adhesion blockade by antilymphocyte antibody drugs. Nephrol Dial Transplant 8 (1993) 544
29. Bonnefoy-Berard N., Vincent C., and Revillard J.P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51 (1991) 669
30. Michallet M.-C., Preville X., Flacher M., et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins1. Transplantation 75 (2003) 657
31. Preville X., Flacher M., Revillard J.P., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a non-human primate model. Transplantation 71 (2001) 460
32. Crosnier J., Kreis H., Descamps J.M., et al. Are there non-steroid-dependent rejection episodes?. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 17 (1980) 391
33. Schroeder T.J., First M.R., Mansour M.E., et al. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 14 5 suppl 2 (1989) 14
34. Pomer S., Waldherr R., Mohring K., et al. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic 'high risk' renal transplant recipients: Long-term results. Transplant Proc 24 (1992) 1732
35. Abramowicz D., Goldman M., De Pauwl L., et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 54 (1992) 433
36. Lange H., Muller T.F., Ebel H., et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int 12 (1999) 2
37. Cockfield S.M., Preiksaitis J.K., Jewel L.D., et al. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 56 (1993) 88
38. Kaden J. Optimal management of induction therapy with ATG in kidney allograft recipients. Int J Immunother 15 (1999) 115
39. Barth R.F., Southworth J., and Burger G.M. Studies on heterologous antilymphocyte and antithymocyte sera. Serologic specificity and immunosuppressive activity of rabbit anti-mouse sera on the primary immune response. J Immunol 101 (1968) 282
40. James K., and Milne I. The effect of antilymphocytic antibody on the primary immune response of mice to sheep erythrocytes, bovine serum albumin, and type 3 pneumococcus polysaccharide. Transplantation 12 (1971) 109
41. Ghaffar A., and James K. The effect of antilymphocytic antibody on the humoral immune response of different strains of mice. IV. Variable effect of individual ALG preparations on the immune response to type III polysaccharide antigen. Immunology 26 (1974) 11
42. Okumura K., Tada T., and Ochiai T. Effect of antithymocyte serum on reaginic antibody formation in the rat. Immunology 26 (1974) 257
43. Reuben C., Sundaram K., and Phondke G.P. Suppression of primary immune response by heterologous anti-lymphocyte sera. Immunology 34 (1978) 223
44. Biesecker J.L., Fitch F.W., Rowley D.A., et al. Cellular and humoral immunity after transplantation in the rat. IV. The effect of heterologous antilymphocyte serum on cellular and humoral immunity after allogeneic renal transplantation. Transplantation 16 (1973) 441
45. Kaden J., May G., Mtiller P., et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc 27 (1995) 1060
46. St Hillier Y., Hory B., Racadot E., et al. Massive systemic endogenous IL-10 release before and at the time of human kidney transplantation. Positive clinical experience on delayed graft function, acute rejection and long-term survival in 62 high risk patients (1998) 319 (Abstract 1648) Proceedings of the XVIIth World Congress of the Transplantation Society, Montreal, July 12-17
47. Abudher M.N., Moorhead J.F., Fernando D.N., et al. Preoperative ATG bolus treatment increase CSA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients. Transplant Proc 31 (1999) 3361
48. Varghese Z., Abudher M.N., Fernando O.N., et al. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients. Transplant Proc 33 (2001) 2251
49. Yussim A., and Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - A prospective, randomized study. Transplant Int 13 suppl 1 (2000) S293
50. Von Woellwarth J., Behrend M., Sehlitt H.J., et al. Ergebnisse der nierentransplantation bei immunologischen risiko-patienten unter einer dreifach-therapie mit mycophenolat-mofetil. Transplant Med 8 (1996) S50
51. Schnitzler M.A., Woodward R.S., Lowell J.A., et al. Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection. Pharmacoeconomics 17 (2000) 287
52. Walters S.J., Whitfield M., Akehurst R.L., et al. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Pharmacoeconomics 21 (2003) 129
53. Polsky D., Weinfurt K.P., and Kaplan B. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol Dial Transplant 16 (2001) 1028
54. Lilliu H., Brun C., Le Pen C., et al. Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. Transplant Proc 33 (2001) 3197
55. Keown P.A., Balshaw R., Krueger H., et al. Economic analysis of basiliximab in renal transplantation. Transplantation 71 (2001) 1573
56. Ballal H.S. Multinational observational study in transplantation (2006) Neocon, Bangalore, India, October 14
57. Nayak K.S. Polyclonal antibodies in renal transplantation (2006) XVIIth Annual Conference of Indian Society of Organ Transplantation, Ahmedabad, India, October 6-8
58. Kaden J., May G., Schonemann C., et al. Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transpl Int 5 Suppl 1 (1992) S75
59. Zietse R., Van Steenberge E.P., Hesse C.J., et al. Single shot, high-dose rabbit ATG for rejection prophylaxis after kidney transplantation. Transpl Int 6 (1993) 337
60. Samsel R., Chmura A., Wlodarczyk Z., et al. Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation-preliminary results. Ann Transplant 4 (1999) 37
61. Yussim A., and Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation-a prospective, randomized study. Transpl Int 13 Suppl 1 (2000) S293
62. Martins L., Henriques A.C., Dias L., et al. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results. Transplant Proc 32 (2000) 2623
63. Nampoory M.R., Abdulhalim M., Johny K.V., et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 34 (2002) 2916
64. Kumar A., Zaman W., Chaurasia D., et al. Prospective randomized trial to evaluate the efficacy of single low dose G induction in renal transplant recipient with spouse a kidney 18 (2002) 58
65. Tullius S.G., Pratschke J., Strobelt V., et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 35 (2003) 2100
66. Abou-Jaoude M.M., and Almawi W.Y. Intraoperative anti-thymocyte globulin-fresenius (ATG-F) administrationas induction immunosuppressive therapy in kidney transplantation. Mol Immunol 39 (2003) 1089
67. Abou-Jaoude M.M., Ghantous I., and Almawi W.Y. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol 39 (2003) 1083
68. Abou-Jaoude M.M., Ghantous I., and Najm R. Intraoperative anti-thymocyte globulin-fresenius bolus induction therapy in kidney transplantation. Transplant Proc 35 (2003) 2729
69. Abou-Jaoude M.M., Ghantous I., and Najm R. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant Proc 35 (2003) 2731
70. Khauli R.B., Houjaij A., and Sawah S. Observations on quadruple immunosuppression maintenance therapy using rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following ATG induction. Transplant Proc 37 (2005) 3031
71. Schulz T., Papapostolou G., and Schenker P. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-fresenius versus thymoglobulin. transpl Proc 37 (2005) 1301